progestin
A progestogen, also referred to as a progestagen, gestagen, or gestogen, is a type of medication which produces effects similar to those of the natural female sex hormone progesterone in the body. A progestin is a synthetic progestogen. Progestogens are used most commonly in hormonal birth control and menopausal hormone therapy. They can also be used in the treatment of gynecological conditions, to support fertility and pregnancy, to lower sex hormone levels for various purposes, and for other indications. Progestogens are used alone or in combination with estrogens. They are available in a wide variety of formulations and for use by many different routes of administration. Examples of progestogens include natural or bioidentical progesterone as well as progestins such as medroxyprogesterone acetate and norethisterone. — Wikipedia
Clinical trial activity
39 trials · 50 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 1994 (NCT00000549)
Timeline
Indications
Approved for
Studied for
- Amenorrhea · Phase 2
- Bone Density · Phase 2
- Bone Diseases · Phase 3
- Bone Diseases, Metabolic · Phase 3
- Breast Feeding · Phase 4
- Breast Neoplasms · Phase 3
- Cardiovascular Diseases · Phase 3
- Colonic Neoplasms · Phase 3
- Contraception · Phase 4
- Contraception Behavior · Phase 4
- Contraceptives, Oral · Phase 4
- Coronary Artery Disease · Phase 3
- Coronary Disease · Phase 3
- Endometrial Hyperplasia · Phase 3
- Endometrial Neoplasms · Phase 2
- Estrogen Replacement Therapy · Phase 1
- Fertility · Phase 4
- Fertilization in Vitro · Phase 4
- Heart Diseases · Phase 3
- HIV · Phase 4
- HIV Infections · Phase 3
- Infertility · Phase 4
- Leiomyoma · Phase 3
- Live Birth · Phase 3
- Menopause · Phase 4
- Menstruation Disturbances · Phase 4
- Mental Health · Phase 4
- Migraine Disorders · Phase 1
- Multiple Sclerosis · Phase 2
- Multiple Sclerosis, Chronic Progressive · Phase 2
- Multiple Sclerosis, Relapsing-Remitting · Phase 2
- Myocardial Ischemia · Phase 3
- Osteoporosis · Phase 3
- Ovarian Neoplasms · Phase 3
- Polycystic Ovary Syndrome · Phase 4
- Postmenopause · Phase 3
- Reproduction · Phase 4
- Sexual Behavior · Phase 4
- Sleep Apnea, Obstructive · Phase 4
- Sleep Initiation and Maintenance Disorders · Phase 4
Mechanism of action
- Androgen ReceptorAGONIST
AR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaProgestogen (medication) ↗
- WikipediaProgestin ↗
- WikipediaCombined oral contraceptive pill ↗
Also known as
- combined oral contraceptive pill
- estroprogestins
- progestin
- progestin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06904274 | Phase 3 | Dec 1, 2025 | Bayer |
| NCT07010146 | Phase 2 | Jul 1, 2025 | National Institutes of Health (NIH), University of Virginia |
| NCT06914297 | Phase 2 | Apr 21, 2025 | Fudan University |
| NCT06672016 | Phase 3 | Dec 31, 2024 | Mylan |
| NCT06396390 | Phase 4 | Aug 1, 2024 | Nesta Clinic |
| NCT06306404 | Phase 4 | Jun 1, 2024 | Netherlands Brain Foundation, ZonMw: The Netherlands Organisation for Health Research and Development |
| NCT06212102 | Phase 2 | Feb 29, 2024 | Bedaya Hospital, Cairo University |
| NCT05903131 | Phase 2 | Jan 31, 2024 | National Cancer Institute (NCI), Washington University in St. Louis |
| NCT05829460 | Phase 2 | Oct 31, 2023 | Novo Nordisk, Washington University in St. Louis |
| NCT06048536 | Phase 2 | Mar 7, 2023 | Mylan |
| NCT05244811 | Phase 3 | Feb 20, 2022 | Sohag University |
| NCT05050357 | N/A | Oct 1, 2021 | Assiut University |
| NCT04965116 | Phase 4 | Sep 28, 2021 | University of California, San Diego |
| NCT04396730 | Phase 4 | Apr 8, 2020 | Oregon Health and Science University, Society of Family Planning |
| NCT06560944 | N/A | Jan 17, 2020 | University of Lincoln |
| NCT03297216 | Phase 3 | Feb 7, 2018 | AMAG Pharmaceuticals, Inc., Bill and Melinda Gates Foundation, National Institutes of Health (NIH), University of North Carolina at Chapel Hill |
| NCT03077698 | Phase 2 | Jun 14, 2017 | Xenetic Biosciences, Inc. |
| NCT04008966 | Phase 4 | Jul 20, 2016 | Cairo University |
| NCT02735551 | Phase 4 | Apr 1, 2016 | Bayer, Merck, Oregon Health and Science University, Society of Family Planning |
| NCT02792517 | Phase 1 | Feb 12, 2016 | Amgen |